FLUTICASONE
Cytomegalovirus Retinitis
Small moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Cytomegalovirus Retinitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ganciclovir | Phase 4 | A |
cidofovir National Center for Research Resources (NCRR) | Phase 4 | BBB |
Foscarnet | Phase 2 | BBB |
Probenecid | Phase 4 | BB |
Sargramostim | Phase 3 | BB |
View all 11 →
Same molecule, other indications
FLUTICASONE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →